title: Cytostatic action of enamel matrix derivative (EMDOGAIN) on human oral squamous cell carcinoma-derived SCC25 epithelial cells.
abstract: During surgical treatment of periodontal disease, enamel matrix derivative (EMD) is topically applied as a substitute for extracellular matrix in order to facilitate regeneration of damaged periodontal tissue. However, the mechanism for EMD action is poorly understood. We have now examined the effects of EMD on the proliferation of oral epithelial (SCC25) cells in vitro. After 3 days of treatments, EMD (25 100 microg/ml) dose-dependently inhibited cell division and concomitantly arrested cell cycle at the G1 phase. Prior to this inhibition, EMD significantly up-regulated p21WAF1/cip1, a cyclin-dependent kinase inhibitor, induced G1-arrest, and inhibited DNA synthesis. In addition, EMD down-regulated expression of cytokeratin-18 (CK18) protein, which was most due to decreased production, but less to increased degradation. However, EMD did not discernibly increase the number of apoptotic cells over 8 days of treatment. These findings indicate (1) that EMD acts as a cytostatic agent, rather than a cytotoxic agent, on epithelial cells, and (2) that this anti-proliferative action is probably due to p21WAF1/cip1-mediated G1-arrest. Furthermore, our in vitro cellular data clearly verify and provide an explanation for the clinical observation that EMD application suppresses the down-growth of junctional epithelium onto dental root surfaces, a process that frequently interferes with the formation of new connective tissue attachments.
authors.affiliation: Department of Pharmacology, Faculty of Dentistry, Niigata University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kawase
authors.forename: K
authors.initials: K
authors.lastname: Okuda
authors.forename: H
authors.initials: H
authors.lastname: Yoshie
authors.forename: D M
authors.initials: DM
authors.lastname: Burns
mesh_terms: D000293:Adolescent; D000704:Analysis of Variance; D017209:Apoptosis / Q000187:drug effects*; D002294:Carcinoma, Squamous Cell; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D016213:Cyclins / Q000378:metabolism; D004261:DNA Replication / Q000187:drug effects; D003746:Dental Enamel Proteins / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000378:metabolism; D004847:Epithelial Cells / Q000187:drug effects*; D005347:Fibroblasts / Q000187:drug effects; D016193:G1 Phase / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007633:Keratins / Q000037:antagonists & inhibitors; D010513:Periodontal Ligament / Q000166:cytology / Q000187:drug effects*; D018709:Statistics, Nonparametric; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D003746:Dental Enamel Proteins; D004791:Enzyme Inhibitors; C109069:enamel matrix proteins; D007633:Keratins; D018844:Cyclin-Dependent Kinases